INGELHEIM, Germany & INDIANAPOLIS--(BUSINESS WIRE)--Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) presented results from a randomised Phase III clinical trial and a post-hoc analysis for linagliptin at ADA. The results showed that adults with type 2 diabetes (T2D) treated with linagliptin in combination with certain other diabetes therapies achieved clinically meaningful blood glucose control.1,2 Linagliptin is a once-daily tablet that is used along with diet and exercise to improve glycaemic control in adults with T2D.3,4
